28 October 2024
28 October 2024
BrainSpec’s MRS platform identified previously undetected injuries in 90% of traumatic brain injury cases.
The partnership between the German company and the NHS trusts is designed to drive the adoption of AI-based radiology systems to speed up diagnostics and cut hospital times for patients.
This development brings the medical community closer to a tool for earlier and more accurate diagnosis.
The company is preparing to launch an early feasibility study in the US to further evaluate the treatment for coronary lesions.
A portion of the proceeds will support the ongoing evidence development for EchoMark and EchoSure, including the MAFASA trial.
The AI market will be worth over $1tn by 2030, and burnt out health professionals could see pressures ease as a result.
It is suggested that the platforms could influence patients in favour of the pharma giants or lead to inappropriate prescribing.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
